Literature DB >> 1151132

In vitro formation and i vivo clearance of fibrinogen: fibrin complexes.

L A Sherman, S Harwig, J Lee.   

Abstract

Fbrinogen:fibrin complexes have been previously described in various thrombotic disorders. To evaluate further the properties of fibrinogen:fibrin complexes, and theirin vitro and in vivo behavior, soluable fibrinogen:fibrin complexes have been formed invitro using mixtures of '131l-fibrinogen ('131l-F) and '125l-fibrin ('125l-fb). By means of Sepharose 4B chromatography, a macromolecular complex (peak one) containing both moieties could be separated from a lower molecular weight peak two containg noncomplexed material. The latter eluted at the same position as did intact fibrogen. Both the '131l-F and '125l-fb components of peak one were rapidly catabolized when injected into rabbits with residual blood activity at 24 hours of 8 per cent and 4 per cent, respectively. Peak two behavedas a simple mixture with corresponding 24-hour levels at 31 per cent and 3 per cent. Gel filtration of postinjuection plasma samples demonstrated that peak one remained as macromolecular complex. Preinjection crosslinking of the F:fb complex with factor xiii did not substantially change the blood clearance. Prior blockage of the reticuloendotheial system with Thorotrast or carbon resulted in impaired clearance of peak one. The data provide evidence that fibrinogen and fibrin can form a macromolecular complex which is stable both in vitro and vivo. Further, the reticuloendotheialsystem was shown to mediate the the in vivo clearance of this complex. This latterfinding may be of pathophysiologic significance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1151132

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes.

Authors:  Sergiy Yakovlev; Leonid Medved
Journal:  Thromb Res       Date:  2017-11-21       Impact factor: 3.944

2.  Adsorptive endocytosis of fibrin monomer by macrophages: evidence of a receptor for the amino terminus of the fibrin alpha chain.

Authors:  S R Gonda; J R Shainoff
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

3.  Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction.

Authors:  F N Rowland; M J Donovan; P T Picciano; G D Wilner; D L Kreutzer
Journal:  Am J Pathol       Date:  1984-12       Impact factor: 4.307

Review 4.  Fibronectin: a review of its structure and biological activity.

Authors:  E Pearlstein; L I Gold; A Garcia-Pardo
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

5.  The predictive value of plasma fibronectin concentration on fetal growth retardation at earlier stage of the third trimester.

Authors:  Z Wang; G Xiong; Y Zhu
Journal:  J Tongji Med Univ       Date:  2001

6.  The localization of fibronectin in rheumatoid arthritis synovium by light and electron microscopic immunohistochemistry.

Authors:  T Matsubara; M A Spycher; J R Rüttner; K Fehr
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

7.  Reticuloendothelial clearance of blood-borne particulates: relevance to experimental lung microembolization and vascular injury.

Authors:  G D Niehaus; P R Schumacker; T M Saba
Journal:  Ann Surg       Date:  1980-04       Impact factor: 12.969

8.  Prevention of liver reticuloendothelial systemic host defense failure after surgery by intravenous opsonic glycoprotein therapy.

Authors:  T M Saba
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

9.  Specific binding of soluble fibrin to macrophages.

Authors:  L A Sherman; J Lee
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.